These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 11126201

  • 1. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ, Weeratna RD, Davis HL.
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [Abstract] [Full Text] [Related]

  • 2. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ, Weeratna RD, Clements JD, Davis HL.
    Vaccine; 2001 Jun 14; 19(27):3759-68. PubMed ID: 11395211
    [Abstract] [Full Text] [Related]

  • 3. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.
    FEMS Immunol Med Microbiol; 2002 Feb 18; 32(3):179-85. PubMed ID: 11934561
    [Abstract] [Full Text] [Related]

  • 4. CpG DNA as mucosal adjuvant.
    McCluskie MJ, Davis HL.
    Vaccine; 1999 Sep 18; 18(3-4):231-7. PubMed ID: 10506647
    [Abstract] [Full Text] [Related]

  • 5. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J, Adamsson J, Harandi AM.
    Scand J Immunol; 2008 May 18; 67(5):431-40. PubMed ID: 18298617
    [Abstract] [Full Text] [Related]

  • 6. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 7. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM.
    J Immunol; 1998 Jan 15; 160(2):870-6. PubMed ID: 9551923
    [Abstract] [Full Text] [Related]

  • 8. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ, Davis HL.
    J Immunol; 1998 Nov 01; 161(9):4463-6. PubMed ID: 9794366
    [Abstract] [Full Text] [Related]

  • 9. CpG DNA is an effective oral adjuvant to protein antigens in mice.
    McCluskie MJ, Weeratna RD, Krieg AM, Davis HL.
    Vaccine; 2000 Nov 22; 19(7-8):950-7. PubMed ID: 11115721
    [Abstract] [Full Text] [Related]

  • 10. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.
    Immunol Lett; 2005 Mar 15; 97(2):181-8. PubMed ID: 15752556
    [Abstract] [Full Text] [Related]

  • 11. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M, Metzger DJ, Michalek SM, Connell TD, Russell MW.
    Infect Immun; 2000 Jan 15; 68(1):281-7. PubMed ID: 10603399
    [Abstract] [Full Text] [Related]

  • 12. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.
    FEMS Immunol Med Microbiol; 2001 Dec 15; 32(1):65-71. PubMed ID: 11750224
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
    Diwan M, Tafaghodi M, Samuel J.
    J Control Release; 2002 Dec 13; 85(1-3):247-62. PubMed ID: 12480329
    [Abstract] [Full Text] [Related]

  • 14. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
    McCluskie MJ, Davis HL.
    Vaccine; 2000 Oct 15; 19(4-5):413-22. PubMed ID: 11027803
    [Abstract] [Full Text] [Related]

  • 15. Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery.
    Bhat AA, Seth RK, Babu J, Biswas S, Rao DN.
    Int Immunopharmacol; 2009 Sep 15; 9(10):1197-208. PubMed ID: 19595793
    [Abstract] [Full Text] [Related]

  • 16. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ, Weeratna RD, Davis HL.
    Vaccine; 2001 Mar 21; 19(17-19):2657-60. PubMed ID: 11257405
    [Abstract] [Full Text] [Related]

  • 17. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.
    Bonenfant C, Dimier-Poisson I, Velge-Roussel F, Buzoni-Gatel D, Del Giudice G, Rappuoli R, Bout D.
    Infect Immun; 2001 Mar 21; 69(3):1605-12. PubMed ID: 11179334
    [Abstract] [Full Text] [Related]

  • 18. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ, McNeela E, Murphy GA, Stewart H, O'hagan D, Pizza M, Rappuoli R, Mills KH.
    Infect Immun; 1999 Dec 21; 67(12):6270-80. PubMed ID: 10569737
    [Abstract] [Full Text] [Related]

  • 19. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
    Adamsson J, Lindblad M, Lundqvist A, Kelly D, Holmgren J, Harandi AM.
    J Immunol; 2006 Apr 15; 176(8):4902-13. PubMed ID: 16585586
    [Abstract] [Full Text] [Related]

  • 20. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J.
    APMIS; 2000 Mar 15; 108(3):178-86. PubMed ID: 10752686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.